Shares of Check Cap Ltd. (NASDAQ:CHEK) soared on Tuesday in response to positive clinical study results for its patient-friendly C-Scan, which is the first capsule-based system for colorectal cancer screening.
Check Cap popped nearly 8% to US$5 in morning trade.
The Isfiya, Israeli, clinical-stage medical-diagnostics company, is focused on the development of a capsule-based system that utilizes low-dose X-rays for colon screening to detect structural abnormalities that may be precancerous or cancerous polyps and colorectal cancers.
Unlike existing tests, C-Scan combines X-ray and location info to create a 3D map of the contours on the inside of the colon for physician review.
A study published in the British journal Gut highlighted the value proposition of C-Scan compared to a traditional screening test called fecal immunochemical test (FIT).
In 45 patients, the sensitivity of C-Scan was 44% compared to 37% for FIT. C-Scan's sensitivity increased to 78% when more than 50% of the colon surface area was imaged through colonoscopy.
In a retrospective analysis using an updated scanning algorithm, the sensitivity of C-Scan rose to 91% in cases were more than half of the colon was imaged.
Designed to be patient-friendly, C-Scan is hoping to increase people’s willingness to go through recommended annual colorectal cancer screening. The Israeli firm’s preparation-free screening gets rid of frequently-cited barriers linked to more invasive screening methods requiring sedatives.